期刊文献+

蜕皮甾酮在Caco-2细胞模型中的摄取和跨膜转运研究 被引量:2

Transport and uptake of ecdysterone in Caco-2 cell monolayers
下载PDF
导出
摘要 目的以Caco-2细胞单层模型,首次研究了蜕皮甾酮的口服吸收与转运特性。方法采用普通Caco-2细胞模型、表达活性CYP3A4酶的Caco-2细胞模型,分别从AP→BL方向和BL→AP方向研究蜕皮甾酮的摄取和跨膜转运规律。结果蜕皮甾酮在2种模型中的表观渗透系数(Papp)在0.1×10-6~1×10-6cm.s-1之间,药物吸收情况为1%~10%;在4 h的实验过程中,4种浓度蜕皮甾酮的ER值均小于1.5。结论研究表明,蜕皮甾酮主要以被动扩散的方式被细胞摄取和转运,其跨膜转运特性未受到CYP3A4-介导机制的影响。 Aim This study examined the uptake and transport of ecdysterone (EDS) using Caco-2 cell monolayers as a model of human intestinal mucosa. Methods Two kinds of Caco-2 cell monolayer model ( Caco-2 cell monolayers; CYP3A4 expressing Caco-2 cell monolayers) were set up to study the uptake and transport of EDS. Results Compared bi-directional charaterizaton of Caco-2 cell, the apparent permeability coefficients (Papp) values of EDS were between 0. 1 ×10^-6cm·s^-1 and 1 ×10^-6cm· s^-1 EDS absorption was 1% - 10% for two kinds of Caco-2 models. The Rpapv values were all less than 1.5 for 4 h. Conclusions The uptake and transport of EDS was a passive tran- seellular diffusion mechanism. Ecdysterone was not influeneed by CYP3A4 mediate mechanism.
出处 《中国药理学通报》 CAS CSCD 北大核心 2009年第4期545-548,共4页 Chinese Pharmacological Bulletin
基金 重庆市重大科技专项资助课题[No渝科发计字(2004)27号]
关键词 蜕皮甾酮 CACO-2细胞模型 25-二羟维生素D3 体外吸收 eedysterone Caco-2 cell monolayer 1α, 25-dihydroxyvitamin D3 in vitro absorption
  • 相关文献

参考文献9

二级参考文献36

  • 1陈秋,夏永鹏,邱宗荫.蜕皮甾酮对HepG2细胞葡萄糖消耗的影响[J].中国药理学通报,2005,21(11):1358-1362. 被引量:17
  • 2陈秋,夏永鹏,邱宗荫.吡格列酮对胰岛素抵抗HepG2细胞模型的药理学评价[J].中国药理学通报,2006,22(2):248-251. 被引量:33
  • 3陈纪岳,胡明,朱彦平.药物从人小肠上皮细胞模型排放的动力学模型[J].上海医科大学学报,1996,23(4):247-251. 被引量:8
  • 4Hoffermeyers S, Burk O, von Richter 0 et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 2000,97:3473-8.
  • 5Parreboom A, Van Asperen J, Mayer U et al, Limited oral bioavailability and active eothelial excertion of paclitaxel(Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA, 1997,94:2031-5.
  • 6Meerm Terwogt JM, Beijnen JH, ten Bokkel Huinink WW et al. Co-adiministratlon of cyclosporin enables oral therapy with paclitaxel. Lancet, 1998;352:285.
  • 7Kim Rb, Fromm MF, Wandel C etal. The drug transporter P-glycoprotein limits oral absoption and brain entry of HIV-1 protease inhibitors. J Clin Invest, 1998 ; 101 : 289-94.
  • 8Schellen JHM, Malingre MM, Kruijtzer CMF et al. Modulaton of oral bioavailability of antieaneer drugs: From mouse to man. Eur J Pharma Sci, 2000;12:103-10.
  • 9Bent LZ, Kroetz DL, Sheiner LB. Pharmacokkinetics: The dynamics of drug absorption, distribution, and elimination. In:Hardman JH, Limbird LE, Molinoff PB, et al., editors.Goodman & Gilman's the pharmacological basis of therapetics.New York, McGraw-Hill. 1996,3-28.
  • 10Wacher VJ, Silverman JA, Zhang Y et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidominetics. J Pharm Sci, 1998;87:1322-30.

共引文献123

同被引文献9

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部